Understanding the efficacy and tolerability of topical therapies for epidermolysis bullosa
Expert Review of Clinical Pharmacology · 04.03.2026 · 19 (3) · 269-273
DOI: 10.1080/17512433.2026.2641138 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, online erschienen am 08.03.2026. Verfasst von Sophie Andreou und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, St George Hospital, Sydney, NSW, Australia. Hauptthemen laut MEDLINE: Epidermolysis Bullosa, Dermatologic Agents, Anti-Inflammatory Agents. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Australasian Blistering Diseases Foundation.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, St George Hospital, Sydney, NSW, Australia.
- University of New South Wales, Sydney, NSW, Australia.
- The George Institute for Global Health, Sydney, NSW, Australia.
ORCID-Profile: Dédée F Murrell
Förderung
- Australasian Blistering Diseases Foundation
Zitieren
APA
Andreou, S., Sarsam, S., & Murrell, D. F. (2026). Understanding the efficacy and tolerability of topical therapies for epidermolysis bullosa. Expert Review of Clinical Pharmacology, 19(3), 269-273. https://doi.org/10.1080/17512433.2026.2641138
Vancouver
Andreou S, Sarsam S, Murrell DF. Understanding the efficacy and tolerability of topical therapies for epidermolysis bullosa. Expert Review of Clinical Pharmacology. 2026;19(3):269-273. doi:10.1080/17512433.2026.2641138
BibTeX
@article{Andreou2026,
author = {Andreou, Sophie and Sarsam, Sera and Murrell, Dédée F},
title = {Understanding the efficacy and tolerability of topical therapies for epidermolysis bullosa},
journal = {Expert Review of Clinical Pharmacology},
year = {2026},
volume = {19},
number = {3},
pages = {269--273},
doi = {10.1080/17512433.2026.2641138}
}
EUVIMED